Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 and FUTURE 3)
Wallman JK, Schett G, Mcinnes IB, Quebe-Fehling E, Rasouliyan L, Pricop L, Gaillez C, Fasth AE (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 47
Pages Range: 36-37
DOI: 10.1136/annrheumdis-2018-eular.2024
Authors with CRIS profile
Involved external institutions
RTI Health Solutions
United States (USA) (US)
University of Glasgow
United Kingdom (GB)
Novartis AG
Switzerland (CH)
Novartis Sverige AB
Sweden (SE)
Lund University / Lunds universitet
Sweden (SE)
United States (USA) (US)
University of Glasgow
United Kingdom (GB)
Novartis AG
Switzerland (CH)
Novartis Sverige AB
Sweden (SE)
Lund University / Lunds universitet
Sweden (SE)
How to cite
APA:
Wallman, J.K., Schett, G., Mcinnes, I.B., Quebe-Fehling, E., Rasouliyan, L., Pricop, L.,... Fasth, A.E. (2018). Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 and FUTURE 3). (pp. 36-37).
MLA:
Wallman, J. K., et al. "Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 and FUTURE 3)." 2018. 36-37.
BibTeX: Download